3 Risk Stratification in MF

MyelofibrosisAK

Preface
1 Introduction
2 MPN-SAF Total Symptom Score (TSS)
3 Risk Stratification in MF
4 Pulmonary Hypertension in Myeloproliferative Neoplasms
5 JAK inhibitors in Myelofibrosis
6 Pacritinib data
7 prePMF vs ET
8 Anemia in MF
9 JAK inhibitor combination therapies
10 Selinexor in MF
11 Mutant CALR targeted Therapies
12 INCA33989 Phase 1 Clinical Trial Results in Myelofibrosis - ASH 2025 Update
13 Disease modification in Myelofibrosis
14 Transplant in Myelofibrosis
15 Summary
References

Table of contents

3.1 Overview of all the Risk-stratfication systems in MF
3.2 DIPSS
3.3 DIPSS Plus
3.4 MYSEC-PM for Post-ET/PV MF
3.5 MTSS

3 Risk Stratification in MF

3.1 Overview of all the Risk-stratfication systems in MF

3.2 DIPSS

3.3 DIPSS Plus

3.4 MYSEC-PM for Post-ET/PV MF

3.5 MTSS

2 MPN-SAF Total Symptom Score (TSS)

4 Pulmonary Hypertension in Myeloproliferative Neoplasms

Source Code

---
title: "Risk Stratification in MF"
---

## Overview of all the Risk-stratfication systems in MF

```{r}
```

## DIPSS


## DIPSS Plus


## MYSEC-PM for Post-ET/PV MF

## MTSS